mls-1 Antibody
Description
Biological Context of Mls-1 Antigen
The Minor Lymphocyte Stimulating-1 (Mls-1) antigen functions as a endogenous superantigen encoded by mouse mammary tumor virus (MMTV) genomes . These antigens induce massive T-cell proliferation by interacting with specific Vβ regions of T-cell receptors.
Key characteristics:
-
Causes clonal deletion of reactive T cells during thymic development
-
Alters host immune repertoire through positive/negative selection mechanisms
Research Findings on Mls-1a Superantigen
From experimental studies in murine models :
| Parameter | Mls-1a Effect | Experimental Evidence |
|---|---|---|
| Vβ14+ T cells | 2.3-fold increase | Flow cytometry analysis of thymocytes |
| Clonal deletion | 89% reduction in reactive cells | Neonatal tolerance studies |
| Positive selection | Confirmed through bone marrow chimeras | Genetic linkage analysis |
Key mechanistic insights:
-
Mls-1a expression induces both deletion and selection processes
-
Superantigen activity persists through multiple generations
Comparative Analysis of Similar Antibodies
From characterized antibodies targeting viral antigens:
Recommended Research Directions
Based on existing immunological frameworks :
-
Epitope characterization
Utilize cryo-EM to resolve Mls-1a structure
Perform alanine scanning mutagenesis -
Functional validation
Develop transgenic mouse models
Establish in vitro T-cell activation assays -
Therapeutic potential assessment Evaluate autoimmune disease modulation Test tumor microenvironment effects
Product Specs
Constituents: 50% Glycerol, 0.01M PBS, pH 7.4
Target Background
Q&A
FAQs for MLS-1 Antibody in Academic Research
Advanced Research Challenges
-
Why does the MLS-1 antibody fail to stain primary lymphocytes despite confirmed Mls-1 activity?
Mls-1 functional activity (T cell deletion/stimulation) correlates with MMTV mRNA expression but not surface protein detection by 3B12 in primary cells. Proposed mechanisms: -
How can researchers resolve discrepancies in Mls-1 detection across cell types?
-
What experimental strategies mitigate non-specific binding in MLS-1 antibody assays?
-
Blocking reagents: Use 5% non-fat milk or 1% BSA in PBS to reduce hydrophobic interactions .
-
Secondary antibody optimization: Select anti-hamster IgG (3B12 host species) with minimal cross-reactivity to mouse serum proteins .
-
Controls: Include Mtv-7-negative cell lines (e.g., LBB.11) and peptide competition assays .
-
Technical Considerations for Experimental Design
-
How to validate MLS-1 antibody specificity in novel cell models?
-
What are the limitations of using MLS-1 antibody in vivo?
-
Low epitope accessibility: Primary lymphocytes evade detection despite functional activity .
-
Temporal constraints: Mls-1-driven T cell deletion occurs during thymic development, limiting adult studies .
-
Cross-reactivity risks: Hamster-derived 3B12 may bind endogenous immunoglobulins in murine models .
-
Data Interpretation and Contradictions
-
How to reconcile Mls-1 antibody results with conflicting T cell response data?
-
Case example: Anergy induction in Vβ6+ T cells (lack of IL-2 production) vs. deletion in immature T cells .
-
Resolution: Distinguish between central (thymic deletion) and peripheral (anergy) tolerance mechanisms using timed experiments .
-
Tools: Pair 3B12 staining with anti-Vβ6 TCR flow cytometry to track T cell fate .
-
